Liquidia Technologies (NASDAQ: LQDA) — Perfil da empresa, notícias e dados financeiros
Liquidia Technologies is a biotech firm focused on innovative treatments for pulmonary arterial hypertension and other applications.
Liquidia Technologies
Liquidia Technologies (NASDAQ:LQDA) is a specialized biotech company dedicated to the development and commercialization of novel products in pulmonary arterial hypertension (PAH) and other applications. Utilizing its proprietary PRINT technology, Liquidia focuses on creating precisely engineered particles to enhance the delivery and performance of its therapeutics. The company's lead product candidate, LIQ861, aims to improve the treatment landscape for patients with PAH, demonstrating Liquidia's commitment to addressing unmet medical needs. Beyond LIQ861, Liquidia actively explores the potential of its technology platform across various therapeutic areas, signaling its objective to expand its pipeline and impact on patient care. Liquidia's operations are driven by a deep-seated commitment to innovation, safety, and efficacy, aiming to secure a prominent position in the specialty pharmaceutical market.
Resumo
Operações
Produtos e/ou serviços de Liquidia Technologies
- YUTREPIA (Treprostinil) Inhalation Powder for pulmonary arterial hypertension, the first and only dry powder inhaled treatment option.
- LIQ861, an investigational inhaled dry powder formulation of treprostinil, designed to improve the therapeutic profile of treprostinil by enhancing deep lung delivery.
- PRINT Technology, a proprietary particle engineering technology used to optimize the delivery and performance of inhaled pharmaceuticals.
- Generic Treprostinil Injection, aimed at providing a more affordable treatment option for pulmonary arterial hypertension.
- Partnership collaborations for the development and commercialization of inhaled therapies, leveraging PRINT technology to enhance treatment efficacy and patient compliance.
- Research and development in nanoparticle-based therapeutics for applications beyond pulmonary conditions, exploring opportunities in oncology and genetic diseases.
equipe executiva do Liquidia Technologies
- Roger A. JeffsCEO & Director
- Michael KasetaCOO & CFO
- Russell SchundlerGeneral Counsel & Corporate Secretary
- Scott MoomawChief Commercial Officer
- Rajeev SaggarChief Medical Officer
- Dana BoyleChief Accounting Officer
- Christian Perez FontSenior VP, Chief Compliance Officer & Associate General Counsel
- Michael PostSenior Vice President of Marketing
- Matt SnowSenior Vice President of Sales
- Sarah KreppChief Human Resources Officer
Últimas notícias sobre a Liquidia Technologies
Liquidia revenue surpasses $170 million in Q2
United StatesLiquidia net sales hit $130M as over 3,750 patients begin YUTREPIA therapy
United StatesLiquidia posts strong YUTREPIA sales as recent launch drives Q4 profit
United StatesLiquidia reports strong preliminary Q4 sales of $90.1M for YUTREPIA
United States
Principais indicadores financeiros
Resultados divulgados pela Liquidia Technologies, em USD.
- Cap. de mercado
- 4,1 bi
- Receita (TTM)
- 450,9 mi
- P/L
- 32.7
- LPA (diluído, TTM)
- 1.4
- Dividend yield
- —
- Margem de lucro
- 30.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 158,3 mi | -51,4 mi | -68,9 mi | |
| 14 mi | -121,3 mi | -130,4 mi | |
| 17,5 mi | -73,4 mi | -78,5 mi | |
| 15,9 mi | -38,8 mi | -41 mi |